Publications

Latest publication 12/01/2014

Polytherapy with a combination of three repurposed drugs -PXT3003- down-regulate

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited sensory and motor peripheral neuropathy. It is caused by PMP22...

Array
(
    [id_prestablog_news] => 670
    [id_shop] => 1
    [date] => 2014-12-01 00:00:00
    [date_modification] => 2024-02-09 14:15:11
    [langues] => ["1","2"]
    [actif] => 1
    [slide] => 0
    [url_redirect] => 
    [average_rating] => 
    [number_rating] => 
    [author_id] => 1
    [featured] => 0
    [prim_key] => 1309
    [id_lang] => 1
    [title] => Polytherapy with a combination of three repurposed drugs -PXT3003- down-regulate
    [paragraph] => Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy
    [content] => 
Authors
Chumakov I, Milet A, Cholet N, Primas G, Boucard A, Pereira Y, Graudens E, Mandel J, Laffaire J, Foucquier J, Glibert F, Bertrand V, Nave KA, Sereda MW, Vial E, Guedj M, Hajj R, Nabirotchkin S, Cohen D.

 Lab
Pharnext, Issy-Les-Moulineaux, France.
Journal
Orphanet J Rare Dis.
Abstract
Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited sensory and motor peripheral neuropathy. It is caused by PMP22 overexpression which leads to defects of peripheral myelination, loss of long axons, and progressive impairment then disability. There is no treatment available despite observations that monotherapeutic interventions slow progression in rodent models. We thus hypothesized that a polytherapeutic approach using several drugs, previously approved for other diseases, could be beneficial by simultaneously targeting PMP22 and pathways important for myelination and axonal integrity. A combination of drugs for CMT1A polytherapy was chosen from a group of authorised drugs for unrelated diseases using a systems biology approach, followed by pharmacological safety considerations. Testing and proof of synergism of these drugs were performed in a co-culture model of DRG neurons and Schwann cells derived from a Pmp22 transgenic rat model of CMT1A. Their ability to lower Pmp22 mRNA in Schwann cells relative to house-keeping genes or to a second myelin transcript (Mpz) was assessed in a clonal cell line expressing these genes. Finally in vivo efficacy of the combination was tested in two models: CMT1A transgenic rats, and mice that recover from a nerve crush injury, a model to assess neuroprotection and regeneration. Combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, termed PXT3003, improved myelination in the Pmp22 transgenic co-culture cellular model, and moderately down-regulated Pmp22 mRNA expression in Schwannoma cells. In both in vitro systems, the combination of drugs was revealed to possess synergistic effects, which provided the rationale for in vivo clinical testing of rodent models. In Pmp22 transgenic CMT1A rats, PXT3003 down-regulated the Pmp22 to Mpz mRNA ratio, improved myelination of small fibres, increased nerve conduction and ameliorated the clinical phenotype. PXT3003 also improved axonal regeneration and remyelination in the murine nerve crush model. Based on these observations in preclinical models, a clinical trial of PTX3003 in CMT1A, a neglected orphan disease, is warranted. If the efficacy of PTX3003 is confirmed, rational polytherapy based on novel combinations of existing non-toxic drugs with pleiotropic effects may represent a promising approach for rapid drug development.
BIOSEB Instruments Used
Dynamic Weight Bearing 2.0 (BIO-DWB-DUAL)
    [meta_description] => 
    [meta_keywords] => http://www.ncbi.nlm.nih.gov/pubmed/25491744
    [meta_title] => 
    [link_rewrite] => polytherapy-with-a-combination-of-three-repurposed-drugs--pxt3003--down-regulates-pmp22-over-expression-and-improves-myelination--axonal-and-functional-parameters-in-models-of-cmt1a-neuropathy
    [actif_langue] => 1
    [read] => 1471
    [count_comments] => 0
    [id] => 670
    [categories] => Array
        (
            [67] => Array
                (
                    [id_prestablog_categorie] => 67
                    [title] => Amyotrophic Lateral Sclerosis (ALS)
                    [link_rewrite] => Amyotrophic-Lateral-Sclerosis-ALS
                )

            [20] => Array
                (
                    [id_prestablog_categorie] => 20
                    [title] => Muscular system
                    [link_rewrite] => Muscular-system
                )

            [2] => Array
                (
                    [id_prestablog_categorie] => 2
                    [title] => Publications
                    [link_rewrite] => publications
                )

        )

    [authors] => 
    [paragraph_crop] => Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 [...]
    [link_for_unique] => 1
    [products_liaison] => Array
        (
            [1216] => Array
                (
                    [name] => Dynamic Weight Bearing 2.0
                    [description_short] => 
The advanced version of our Dynamic Weight Bearing Test for rodents (rats and mice) allows for faster paw identification, based on a video solution taking advantage of the most advanced algorithms of morphologic analysis, weight distribution and postural changes in dynamic conditions. An efficient and advanced alternative to traditional incapacitance tests (i.e. the paw pressure test or the force plate test) for assessing pain sensitivity in your research on analgesia, hyperalgesia and nociception involving rats and mice, including work on osteoarthritis, bone cancer, analgesic substances, Parkinson disease, allodynia...

                    [thumb] => 
                    [img_empty] => /var/www/vhosts/de3310.ispfr.net/preprod.bioseb.com/modules/prestablog/views/img/product_link_white.jpg
                    [image_presente] => 1
                    [link] => https://preprod.bioseb.com/en/pain-spontaneous-pain-postural-deficit/1216-dynamic-weight-bearing-20.html
                )

            [1877] => Array
                (
                    [name] => Dynamic Weight Bearing 2.0 – Postural Module [Add-on]
                    [description_short] => 
Expand Your Analysis with Advanced Postural and Locomotor Calculations
BIOSEB’s renowned Dynamic Weight Bearing (DWB2) system is now more powerful than ever with the addition of the Postural Module. This optional software upgrade extends standard weight-bearing analysis by integrating unique calculations designed to quantify subtle aspects of postural balance, locomotor patterns, and compensatory behaviors.
Developed in collaboration with Dr. Tighilet’s lab from Aix Marseille Université-CNRS, the Postural Module improves your DWB2, providing valuable endpoints for studies on pain, neurology, vestibular dysfunction, and neurodegenerative disorders.

                    [thumb] => 
                    [img_empty] => /var/www/vhosts/de3310.ispfr.net/preprod.bioseb.com/modules/prestablog/views/img/product_link_white.jpg
                    [image_presente] => 1
                    [link] => https://preprod.bioseb.com/en/pain-spontaneous-pain-postural-deficit/1877-dynamic-weight-bearing-20-add-on-postural-module.html
                )

        )

)
1